This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
5ezu
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Crystal structure of the N-terminal domain of vaccinia virus immunomodulator A46 in complex with myristic acid.== | |
| - | + | <StructureSection load='5ezu' size='340' side='right' caption='[[5ezu]], [[Resolution|resolution]] 1.55Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[5ezu]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5EZU OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5EZU FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=MYR:MYRISTIC+ACID'>MYR</scene></td></tr> | |
| - | [[ | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5ezu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ezu OCA], [http://pdbe.org/5ezu PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5ezu RCSB], [http://www.ebi.ac.uk/pdbsum/5ezu PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5ezu ProSAT]</span></td></tr> |
| - | [[Category: | + | </table> |
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/A46_VACCW A46_VACCW]] Bcl-2-like protein which disrupts the host immune response by inhibiting the TLR4 signaling pathway leading to NF-kappa-B activation. Targets several host TIR adapters including MYD88, TIRAP, TRIF and TICAM2 thereby blocking NF-kappa-B and TRIF-mediated IRF3 activation. | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Bezerra, G A]] | ||
[[Category: Fedosyuk, S]] | [[Category: Fedosyuk, S]] | ||
| + | [[Category: Sammito, M]] | ||
[[Category: Skern, T]] | [[Category: Skern, T]] | ||
| - | [[Category: | + | [[Category: Uson, I]] |
| - | [[Category: | + | [[Category: A46]] |
| + | [[Category: Ab initio phasing]] | ||
| + | [[Category: Beta sheet]] | ||
| + | [[Category: Fatty acid]] | ||
| + | [[Category: Immunomodulator]] | ||
| + | [[Category: Myristic acid]] | ||
| + | [[Category: Vaccinia virus]] | ||
| + | [[Category: Viral protein]] | ||
Revision as of 18:31, 10 December 2016
Crystal structure of the N-terminal domain of vaccinia virus immunomodulator A46 in complex with myristic acid.
| |||||||||||
